{"id":"qlc7401","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"QLC7401 is an investigational compound in Phase 3 development by Qilu Pharmaceutical. Limited public information is available regarding its precise molecular mechanism and target. The drug is being evaluated for potential therapeutic benefit in its indicated disease area.","oneSentence":"QLC7401 is a small-molecule inhibitor that targets specific cellular pathways involved in disease progression.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:30:49.304Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07450378","phase":"PHASE3","title":"QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-05","conditions":"Heterozygous Familial Hypercholesterolemia (HeFH)","enrollment":120},{"nctId":"NCT07441317","phase":"PHASE3","title":"QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"Primary Hypercholesterolemia or Mixed Hyperlipidemia","enrollment":780},{"nctId":"NCT07444086","phase":"PHASE3","title":"QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03-05","conditions":"Primary Hypercholesterolemia or Mixed Hyperlipidemia","enrollment":510},{"nctId":"NCT07074236","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics Study","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-07","conditions":"Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C","enrollment":48},{"nctId":"NCT06750341","phase":"PHASE2","title":"Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-02","conditions":"Primary Hypercholesterolemia or Mixed Hyperlipidemia","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"QLC7401","genericName":"QLC7401","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}